4-(1,2-二氢-2-氧代-6-喹啉氧基)丁酸甲酯 | 87364-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-(1,2-二氢-2-氧代-6-喹啉氧基)丁酸甲酯
• 英文名称: methyl 4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyrate
• 英文别名: methyl 4-(2-oxo-6-hydroquinolyloxy)butanoate；methyl 4-[(2-oxo-1H-quinolin-6-yl)oxy]butanoate
• CAS: 87364-41-8
• 化学式: C₁₄H₁₅NO₄
• 分子量: 261.277
• InChiKey: MUQYGBZRYIGCNR-UHFFFAOYSA-N

物化性质

• 熔点：
  150.5-152 °C(Solv: methanol (67-56-1))
• 沸点：
  489.6±45.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1,2-二氢-2-氧代-6-喹啉氧基)丁酸甲酯 在 盐酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 氯甲酸异丁酯 作用下， 反应 6.0h， 生成 N-Methyl-4-(2-oxo-1,2-dihydro-quinolin-6-yloxy)-butyramide
  参考文献：
  名称：

  Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-Cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide and related compounds.

  摘要：

  合成了一系列 N,N-取代的ω-(1, 2-二氢-2-氧羟喹啉氧基)烷基氨基酸酰胺，并对其在体外对胶原和ADP诱导的兔血小板聚集的抑制活性进行了测试。这些化合物是通过ω-(1, 2-二氢-2-氧羟喹啉氧基)烷酸与各种胺反应，采用混合酸酐法制备的。其中，N-环己基-N-(2-羟乙基)-4-(1, 2-二氢-2-氧-6-喹啉氧基)丁酰胺（IVa1）被发现具有最强的抑制活性。文中讨论了结构-活性关系。

  DOI：

  10.1248/cpb.31.852
• 作为产物：
  描述：

  6-羟基-2(1H)-喹啉酮 、 4-溴丁酸甲酯 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 异丙醇 为溶剂， 反应 4.0h， 以74%的产率得到4-(1,2-二氢-2-氧代-6-喹啉氧基)丁酸甲酯
  参考文献：
  名称：

  Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-Cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide and related compounds.

  摘要：

  合成了一系列 N,N-取代的ω-(1, 2-二氢-2-氧羟喹啉氧基)烷基氨基酸酰胺，并对其在体外对胶原和ADP诱导的兔血小板聚集的抑制活性进行了测试。这些化合物是通过ω-(1, 2-二氢-2-氧羟喹啉氧基)烷酸与各种胺反应，采用混合酸酐法制备的。其中，N-环己基-N-(2-羟乙基)-4-(1, 2-二氢-2-氧-6-喹啉氧基)丁酰胺（IVa1）被发现具有最强的抑制活性。文中讨论了结构-活性关系。

  DOI：

  10.1248/cpb.31.852

文献信息

• [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY<br/>[FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004033444A1

  公开（公告）日：2004-04-22

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
  申请人：Hamilton S. Gregory

  公开号：US20070066619A1

  公开（公告）日：2007-03-22

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对 PDE-3 和 L 型钙通道抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• [EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE MIXTE D'INHIBITION DE LA PDE ET D'ANTAGONISTE OU D'AGONISTE PARTIEL <supplemental>20041125</supplemental>EP0116948A2SYNTEX INC [US]198408291,27-29A1,25,37,40AEP0355583A2OTSUKA PHARMA CO LTD [JP]1990022872121X37XGB2190676ABRISTOL MYERS CO1987112510521165143X1,25,37XGB1465946ACIBA GEIGY AG19770302411311,23,12428mX1,25,37XEP0029992A1BOEHRINGER MANNHEIM GMBH [DE]198106101,92g,6hX1,25,37XDE2950479A1NATTERMANN A & CIE [DE]19810619811,32,3X1,25,37XUS5641783AKLEIN J PETER [US], et al19970624claims 1, 18 (column 97, line 5) and 21X1,25XGB1488330ASMITH KLINE FRENCH LAB19771012page 3, lines 32-37 and page 4, lines 1-16; claim 1X25,37XEP0138344A2SMITH KLINE FRENCH LAB [GB]19850424page 6, line 13- page 7, line 25X25,37XGB1567907ASMITH KLINE FRENCH LAB19800521page 5, lines 22-23; page 6, lines 51-52;X1XEGUCHI, YUKUO ET AL: "Studies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compounds", CHEMICAL & PHARMACEUTICAL BULLETIN , 39(3), 795-7 CODEN: CPBTAL; ISSN: 0009-2363, 1991, XP001194680EGUCHI, YUKUO ET ALStudies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compoundsCHEMICAL & PHARMACEUTICAL BULLETIN , 39(3), 795-7 CODEN: CPBTAL; ISSN: 0009-23631991compound 10 and table IX1,25,37XM.S. CHODNEKAR ET AL.: "Beta-Adrenergic blocking agents. 11. Heterocyclic analogs of pronethalol[2-isopropylamino-1-(2-naphthyl)ethanol]", JOURNAL OF MEDICINAL CHEMISTRY., vol. 15, no. 1, 1972, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 49 - 57, XP002292174M.S. CHODNEKAR ET AL.Beta-Adrenergic blocking agents. 11. Heterocyclic analogs of pronethalol[2-isopropylamino-1-(2-naphthyl)ethanol]JOURNAL OF MEDICINAL CHEMISTRY.USAMERICAN CHEMICAL SOCIETY. WASHINGTON.19721514957compound 30X37XGB1540628AOTSUKA PHARMA CO LTD197902141,83page 1, lines 6-24; examplesX1,25,37XCROWTHER A F ET AL: "BETA-ADRENERGIC BLOCKING AGENTS. 12. HETEROCYCLIC COMPOUNDS RELATEDTO PROPRANOLOL", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 15, no. 3, 1972, pages 260 - 266, XP000909966, ISSN: 0022-2623CROWTHER A F ET ALBETA-ADRENERGIC BLOCKING AGENTS. 12. HETEROCYCLIC COMPOUNDS RELATEDTO PROPRANOLOLJOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US19721530022-2623260266<table>VII</table>X37XDATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002292176, retrieved from STN Database accession no. 1977:453098NAKAGAWA, KAZUYUKI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1977:453098STNAabstract and compounds 61122-74-5, 61122-75-6, 63423-80-3, 63423-81-4X1,25,37XJPS51125291AOTSUKA PHARMA CO LTD19761101DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002292177, retrieved from STN Database accession no. 1977:89632NAKAGAWA, KAZUYUKI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1977:89632STNAabstract and compounds 61122-74-5 and 61122-75-6X1,25,37XJPS5168575AOTSUKA PHARMA CO LTD19760614DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ISHIKAWA, HIROSHI ET AL: "Carbostyril derivatives", XP002292178, retrieved from STN Database accession no. 1978:509144ISHIKAWA, HIROSHI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1978:509144STNAcompound 67358-84-3X1,25,37XJPS5350182AOTSUKA PHARMA CO LTD19780508DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAKANO, KAZUHISA ET AL: "3,4-Dihydrocarbostyril derivatives", XP002292179, retrieved from STN Database accession no. 1979:405123SAKANO, KAZUHISA ET AL3,4-Dihydrocarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1979:405123STNAcompounds 70386-53-7, 70386-41-3, 63423-80-3X1,25,37XJPS5416478AOTSUKA PHARMA CO LTD19790207DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "Carbostyrils", XP002292180, retrieved from STN Database accession no. 1982:406175CarbostyrilsCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1982:406175STNAcompound 81994-29-8X1,25XJPS5742673AOTSUKA PHARMA CO LTD19820310WO8402908A1POS LAB [FR]1984080213191,4X1,25,37XKIKKAWA, HIDEO ET AL: "The role of the seventh transmembrane region in high affinity binding of a .beta.2-selective agonist TA-2005", MOLECULAR PHARMACOLOGY , 53(1), 128-134 CODEN: MOPMA3; ISSN: 0026-895X, 1998, XP001199449KIKKAWA, HIDEO ET ALThe role of the seventh transmembrane region in high affinity binding of a .beta.2-selective agonist TA-2005MOLECULAR PHARMACOLOGY , 53(1), 128-134 CODEN: MOPMA3; ISSN: 0026-895X1998compounds II and III; abstractX1,25,37XDEYRUP, M. D. ET AL: "Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the .beta.2-adrenoceptor", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY , 359(3), 168-177 CODEN: NSAPCC; ISSN: 0028-1298, 1999, XP001199515DEYRUP, M. D. ET ALStructure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the .beta.2-adrenoceptorNAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY , 359(3), 168-177 CODEN: NSAPCC; ISSN: 0028-12981999compounds 10b, 10c, 10gX1,25,37XWO03015785A1ICOS CORP [US], et al20030227page 51, line 1, column 3PX1,25PXSIVAKUMAR, RAMAIYA ET AL: "Pharmacological evaluation of some new 1-substituted-4-hydroxy- phthalazines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 37(10), 793-801 CODEN: EJMCA5; ISSN: 0223-5234, 2002, XP004393912SIVAKUMAR, RAMAIYA ET ALPharmacological evaluation of some new 1-substituted-4-hydroxy- phthalazinesEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 37(10), 793-801 CODEN: EJMCA5; ISSN: 0223-52342002compounds 5, 7 and 12 and table 1PX1,25PX
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004050657A3

  公开（公告）日：2004-11-25
• NISHI, TAKAO;TABUSA, FUJIO;TANAKA, TATSUYOSHI;UEDA, HIRAKI;SHIMIZU, TAKEF+, CHEM. AND PHARM. BULL., 1983, 31, N 3, 852-860
  作者：NISHI, TAKAO、TABUSA, FUJIO、TANAKA, TATSUYOSHI、UEDA, HIRAKI、SHIMIZU, TAKEF+

  DOI：——

  日期：——
• Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-Cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide and related compounds.
  作者：TAKAO NISHI、FUJIO TABUSA、TATSUYOSHI TANAKA、HIRAKI UEDA、TAKEFUMI SHIMIZU、TOSHIMI KANBE、YUKIO KIMURA、KAZUYUKI NAKAGAWA

  DOI：10.1248/cpb.31.852

  日期：——

  A series of N, N-disubstituted-ω-(1, 2-dihydro-2-oxoquinolyloxy) alkanecarboxamides was synthesized and tested for inhibitory activity towards collagen- and ADP-induced aggregation of rabbit blood platelet in vitro. These compounds were prepared by the reaction of ω-(1, 2-dihydro-2-oxoquinolyloxy) alkanoic acid and various amines by the mixed anhydride method. Among them, N-cyclohexyl-N-(2-hydroxyethyl)-4-(1, 2-dihydro-2-oxo-6-quinolyloxy) butyramide (IVa1) was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.

  合成了一系列 N,N-取代的ω-(1, 2-二氢-2-氧羟喹啉氧基)烷基氨基酸酰胺，并对其在体外对胶原和ADP诱导的兔血小板聚集的抑制活性进行了测试。这些化合物是通过ω-(1, 2-二氢-2-氧羟喹啉氧基)烷酸与各种胺反应，采用混合酸酐法制备的。其中，N-环己基-N-(2-羟乙基)-4-(1, 2-二氢-2-氧-6-喹啉氧基)丁酰胺（IVa1）被发现具有最强的抑制活性。文中讨论了结构-活性关系。